Skip to main content
Premium Trial:

Request an Annual Quote

Modest Amusement Indeed

In the September/October issue of Technology Review, Duke's Misha Angrist says that the authorities in California and New York were "wrongheaded and arrogant" to insist that the services offered by personal genomics companies need to have a physician gatekeeper. True, the tests haven't been validated, and Angrist says that will take years. "This is where we are in the era of personal genomics: some modest amusement, a few interesting tidbits, a bit of useful information, but mostly the promise of much better things to come," writes Angrist.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.